Gingko mihuan
Alternative Names: Gingko Mihuan - Tianyin Pharmaceuticals; Gingko Mihuan - TPI; GMOLLatest Information Update: 29 Dec 2014
At a glance
- Originator Tianyin Pharmaceutical
- Class Cardiovascular therapies; Flavonoids; Glycosides; Terpenes; Traditional Chinese medicine
- Mechanism of Action Antioxidants; Platelet activating factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Angina pectoris; Cardiovascular disorders; Cerebral infarction; Cerebral ischaemia; Coronary disorders; Memory disorders; Neurological disorders; Stroke
Most Recent Events
- 24 Dec 2014 Tianyin Pharmaceuticals and an undisclosed company entered into a research and development agreement for formulation varieties of gingko mihuan
- 17 Jul 2012 Launched for Angina pectoris in China (PO) before July 2012
- 17 Jul 2012 Launched for Cardiovascular disorders in China (PO) before July 2012